Introduction
Screening for inherited metabolic disease has been in place in the UK since the 1960's when screening for Phenylketonuria (PKU) first began. More recently screening for Medium Chain Acyl CoA Dehydrogenase deficiency (MCADD) was introduced and in 2012/13 a study was undertaken to evaluate the utility for screening for other additional IMDs. In May 2014 the UK National Screening Committee announced its recommendation to include four additional inherited metabolic diseases as part of the national newborn screening blood spot programme, maple syrup urine disease (MSUD), isovaleric aciduria (IVA), glutaric aciduria type 1 (GA1) and homocystinuria (HCU). The national IMD screening programme now includes these six IMD conditions. The early detection offered by newborn screening is a significant benefit for patients with all of the conditions included within the programme and in some cases can be lifesaving. The successful introduction of screening depends upon the cohesive management of testing as a programme of care from pre-screening information to screening results and in the case of positive cases enrolment into appropriate treatment. It is important that mothers are fully informed at each stage and that only clinically significant disease is detected with a minimum number of false positive cases. Once a screen positive patient is identified, the period of uncertainty required for any associated confirmatory testing must be kept to a minimum and parents supported during this trying time.
The South West Regional Policy (Bristol Newborn Screening Laboratory) was orginally produced by the SW Regional IMD Implementation Group as a guide for local implementation teams to inform the introduction of newborn screening for the four additional conditions throughout the region. At the same time the regional policies for PKU and MCADD were reviewed and, where possible, aligned to enable the production of a single unified policy for screening for IMD across the SW Region. The policy has now been updated and ratified by the South West Regional Newborn Screening Operational Group to reflect the 2017 updated IMD clinical referral guidelines, the 2017 Newborn Blood Spot Performance Standards and the introduction of Saturday morning reading and reporting of positive newborn screens for the IMD conditions IVA, MCADD & MSUD.
Further information regarding clinical referral pathways and management guidelines can be found on the British Inherited Metabolic Diseases Group (BIMDG) website (https://www.bimdg.org,uk). National Programme Policies, Standards and resources can be found on the website https://www.gov.uk/topic/population-screening-programmes
The conditions
Phenylketonuria Phenylketonuria is one of the most common inherited metabolic disorders with an incidence across the UK of approximately 1 in 10 000 births. PKU is an autosomal recessively inherited disorder of amino acid metabolism caused by a deficiency of the enzyme phenylalanine hydroxylase (PAH). The enzyme is required to metabolise phenylalanine to tyrosine. A deficiency of the enzyme results in an accumulation of phenylalanine and associated metabolites in blood and tissues. The infant brain is sensitive to high phenylalanine levels and if left untreated, patients with PKU develop severe mental retardation, microcephaly and a proportion of patients develop epilepsy. Older patients have behavioural problems and some suffer from psychiatric illness.
Children with PKU requiring treatment are treated with a phenylalanine restricted diet to reduce the flux through the affected metabolic pathway thereby preventing the accumulation of toxic metabolites. Dietary therapy utilises a phenylalanine-free synthetic amino acid mixture as a substitute for natural protein and requires careful management to ensure appropriate vitamins and trace elements together with small amounts of natural protein are provided. Treatment should begin with minimum delay. Recommendations in the past have indicated that diet should be initiated by 20 days of age and continued throughout childhood.
An increased blood phenylalanine is not specific for PKU. In addition to disorders of phenylalanine hydroxylase deficiency, increased phenylalanine on newborn screening at 5-8 days may occur in several other situations. There are several rare disorders of pterin synthesis/recycling which may be associated with an isolated increase in phenylalanine at screening and therefore detected by the PKU programme. All babies with a PKU suspected screening result are tested for pterin disorders at follow up.
In some cases the phenylalanine increase is associated with an increase in tyrosine which is measured as part of the screening protocol. This situation can arise in conditions which cause liver disease in the neonate e.g. hepatitis, biliary atresia, CMV and some inherited disorders, in particular Galactosaemia and Tyrosinaemia type 1. There are also a number of other non-specific causes including prematurity, parenteral nutrition and transient illness. Babies with an associated increase in tyrosine require different investigation and management and urgent referral to an appropriate specialist clinician is essential.
Medium Chain Acyl CoA Dehydrogenase Deficiency
MCADD is an autosomal recessive condition that affects approximately 1 in 10,000 born in the United Kingdom. It is caused by a deficiency of an enzyme medium chain acyl CoA dehydrogenase. This enzyme is required to breakdown certain stored fats, medium chain length fatty acids, and is necessary to enable the body to use its own fat reserves to produce energy in periods of prolonged fasting or stress.
Complications of MCADD can arise during prolonged fasting but particularly occur during intercurrent illness when the body's demand for energy is high and Calorie 5 intake is often reduced. As fat fuels cannot be used these patients quickly use up glucose and can develop hypoglycaemia. Partially broken down fatty acids accumulate and this, along with low blood glucose concentrations, cause these patients to become drowsy, comatose and eventually to stop breathing. Without treatment this condition is associated with significant morbidity and mortality. Early identification by screening however results in early pre-symptomatic treatment reducing the risk of acute life-threatening episodes.
MCADD requires no special treatment when the child is well. Fasting should however be avoided. When illness occurs MCADD is easily treatable with an emergency feeding regime of high calorie drinks or, if unable to tolerate e.g. due to vomiting, urgent hospital admission for an intravenous 10% dextrose infusion. With early detection, monitoring and avoidance of fasts, children diagnosed with MCADD can lead normal lives particularly as 'safe' times between meals increase as they grow older.
Maple Syrup Urine disease
MSUD is an autosomal recessive caused by a deficiency of the branched chain alpha keto acid dehydrogenase complex. The condition occurs in approximately 1:200,000 live births. The resulting metabolic block leads to an increased concentration of the branched chain amino acids leucine, valine and isoleucine and their corresponding keto acids. These compounds accumulate in tissues resulting in a life threatening metabolic decompensation in some affected individuals and are elevated in the blood and urine. The name of the condition derives from the sweet smelling urine sometimes produced by affected individuals which some have likened to the smell of maple syrup.
The classic form of the disorder presents shortly after birth often in the first two weeks of life. Vomiting or difficulty feeding are often early symptoms accompanied by lethargy and progressive neurological deterioration. Intermediate and intermittent forms of the condition are also described. Patients with the intermediate form may present with developmental delay although the characteristic elevation of branched chain amino acids is still present. The intermittent form of the disease may only manifest at times of stress or infection and branched chain amino acids may not be continuously elevated. Rarer thiamine responsive disease has been described together with another variant which also affects the pyruvate dehydrogenase complex resulting in marked lactic acidosis.
It is likely that newborn screening will detect patients with the classic condition but may not detect individuals with intermediate or intermittent forms which have a spectrum of clinical and biochemical severity.
Isovaleric aciduria
Isovaleric acidaemia (IVA) is caused by a deficiency of isovaleryl-CoA dehydrogenase (IVD), an enzyme involved in the catabolism of the amino acid leucine. It is an autosomal recessive disease, with an estimated incidence of around 1 in 100,000 with a higher incidence in some locations and ethnic groups.
Loss of function of the enzyme leads to the toxic build-up of metabolites including isovaleric acid and its glycine and carnitine derivatives. The disease has a spectrum of clinical phenotypes which might include acute neonatal presentations, acute presentations at a later age and chronic intermittent presentations. The acute neonatal presentation is characteristically in the first two weeks after birth. Infants 6 are initially well, then develop vomiting and lethargy, progressing to coma. Patients may also present with similar symptoms at a later age, usually precipitated by an infection. Other patients present with chronic symptoms -failure to thrive and/or developmental delay, usually within the first year.
Over 25 mutations in the IVD gene have been associated with disease, a number of which lead to complete lack of the enzyme. Although a firm phenotype/genotype correlation has not been identified, recent research suggests that the 932C>T mutation in the IVD gene may be associated with a milder phenotype. Newborn screening has identified individuals with partial as well as complete IVD deficiency.
Glutaric aciduria type 1
Glutaric aciduria type 1 (GA1) is an autosomal recessive condition caused by a deficiency of the enzyme glutaryl-CoA dehydrogenase (GCDH). The estimated incidence in the UK is around 1 in 100,000 live births.
GCDH is involved in the metabolism of the amino acids lysine, hydroxylysine, and tryptophan. Defective catabolism causes the toxic accumulation of glutaric acid, 3hydroxyglutaric acid, glutaconic acid, and glutaryl carnitine.
GA1 frequently presents with an encephalopathic crisis, which is most commonly between 9 months to 2 years. These are usually precipitated about 1-3 days after onset of a non-specific intercurrent illness, gastrointestinal infection or pneumonia and lead to dystonia and dyskinesia as permanent sequelae but with relative preservation of the intellect. There are also two other clinically recognised subgroups of patients with GA1 who have an insidious or later onset form with nonspecific symptoms including irritability and transient lactic acidosis. These infants go on to show delayed motor development. Very occasionally an individual might be asymptomatic.
Over 150 disease causing mutations have been identified; of these the R402W mutation is the most prevalent among Caucasians. Most mutations, including the R402W mutation, are associated with undetectable GCDH activity and excretion of high amounts of glutaric acid. However, mutations that lead to varying levels of residual GCDH activity and low excretion of glutaric acid have also been reported. Consequently, patients with GA1 can be divided into two biochemically defined subgroups based on the levels of glutaric acid present in the urine: low excretors and high excretors. Although these subgroups are clinically similar it is important to be aware as confirmatory testing in low excretors requires more complex follow-up, with either determination of GCDH enzyme activity or by mutation analysis of the GCDH gene.
Homocystinuria
The most common cause of homocystinuria is a defect in the enzyme cystathionine -synthase (CBS); this is referred to as "classical" homocystinuria. The overall incidence in the UK is reported to be around 1 in 100,000 live births. The mode of inheritance of classical homocystinuria is autosomal recessive.
Classical homocystinuria is associated with a number of clinical and pathological abnormalities. Infants are usually normal at birth and without screening the diagnosis is not usually made until the first 2-3 years of life. Myopia followed by dislocation of the lens, osteoporosis, thinning and lengthening of the long bones, 7 mental retardation and thromboembolism affecting larger and small arteries and veins are the commonest clinical features. Without treatment, 25% of patients will die before the age of 30, usually as a result of arterial thromboembolism. There is a great deal of clinical heterogeneity, with some patients displaying all clinical symptoms whilst others display very few or none. The concentration of plasma total homocysteine can be measured to assess the clinical severity of disease and can be monitored to determine the response to treatment.
Homocystinuric patients can be sub-divided into two important biochemical phenotypes:
 Pyridoxine responsive (screen undetectable)  Pyridoxine non-responsive (screen detectable)
In the UK approximately 50% of patients with classical homocystinuria are classified as pyridoxine responsive, these patients usually have milder symptoms and disease progression is slower and slowed further by oral pyridoxine (Vitamin B6) supplementation, they are very unlikely to be detected by newborn screening 2 Aims 1.
To offer screening to all babies resident within the area covered by the Bristol Newborn Screening Laboratory 2.
To inform parents of the IMD status of their newborn children.
3.
To minimise morbidity and mortality from PKU, MCADD, MSUD, IVA, GA1 and HCU in infants born within the South West region.
Objectives

1.
To identify and offer screening to all eligible infants.
2.
To process tests for all those screened in a timely manner.
3.
To ensure an appropriate level of understanding amongst professionals involved with the programme.
4.
To appropriately follow up all infants identified as needing further investigative testing.
5.
To accurately diagnose all infants born with PKU, MCADD, MSUD, IVA, GA1 and HCU
6.
To ensure that information is provided to affected families in an acceptable and accessible manner and is appropriate to the needs of the relevant communities.
7.
To ensure effective and acceptable follow up, care and support for infants with PKU, MCADD, MSUD, IVA, GA1 and HCU and their carers.
8.
To audit the service on an ongoing basis and provide information on acceptability, effectiveness and resource implications.
9.
To minimise the adverse effects of screening (anxiety, misunderstanding, inaccurate information, unnecessary investigation and follow-up, and inappropriate disclosure of patient-specific information).
The screening protocols
The newborn screening protocols have been agreed and endorsed by the IMD Scientific Advisory Board. The screening protocols are intended to:-Maximise early detection of PKU, MCADD, MSUD, IVA, GA1 and HCU so that appropriate early pre-symptomatic treatment can be initiated and the risk of acute, life threatening episodes and/or the development of disease associated complications can be reduced.
Minimise the number of false positive results and the detection of unaffected carriers.
Samples will be processed at a laboratory recognised as a newborn blood spot screening laboratory, adhering to the programme laboratory standards and using the recommended standard operating procedures: https://www.gov.uk/topic/population-screening-programmes Note a decline for IMD screening includes all 6 conditions. It will not be possible to decline IMD screening for one or more of the 6 conditions.
6. Ensure the good quality blood spot is collected i.e. sample is taken at the right time, all data fields completed, contains sufficient blood for all tests, is not contaminated and reaches the lab in a timely manner. 4d
Sibling testing
A new sibling born to the same parents when an index case with either PKU, MCADD, MSUD, IVA, GA1 or HCU has already been identified has a 1 in 4 risk of having the same disorder. In these circumstances it is recommended practice to test earlier than the 5-8 day time frame to avoid delays in diagnosis and parental anxiety. This does not remove the need to test at 5-8 days to screen for all other disorders tested as part of the blood spot screening programme.
The decision about when and how to test depends upon the disorder suspected. Note it is most important for disorders such as MSUD, MCADD and IVA which can potentially have an early neonatal presentation.
Older siblings of newly diagnosed screen detected cases, when born to the same parents, have a 1 in 4 chance of having the same disorder. Careful consideration should be given by the clinician investigating the baby referred via screening to the risks to other, older siblings in the family.
For guidance on testing of siblings contact the Regional Specialist Paediatric Metabolic Team and the Newborn Screening Laboratory
Newborn screening results
All screening results will be reported to Child Health Records departments in line with present policies for the Newborn Blood Spot Screening Programme with use of the appropriate status codes. https://www.gov.uk/government/collections/newborn-blood-spot-screeningprogramme-standards-and-data Written policies and mechanisms for relaying of results to parents must be developed locally to include professional responsibility for informing parents of the result, and clear process detail for follow-up of affected babies. Policies should be developed in line with national and regional guidance as detailed below.
5a. Condition 'not suspected'
Newborn screening results which are negative for all of the conditions are to be reported in a timely manner to parents.
Standard 12a -Timeliness of results to parents
Acceptable standard 100% of babies with a not suspected result for each of the conditions for whom a not suspected results letter was despatched directly to parents by the CHIS within 6 weeks of birth.
Standard 12b -Timeliness of results to parents (movers in)
Acceptable standard 100% of babies with a not suspected result for each of the conditions for whom a not suspected results letter was despatched directly to parents by the CHIS within 6 weeks of notification of movement in.
5b
Condition 'suspected'
Babies identified as screen positive should have timely referral into clinical care in line with defined clinical referral pathway see below. Any repeat screening tests should be offered & collected in a timely manner in order that treatment and clinical referral targets are met.
Standard 7
Timely taking of a repeat blood spot sample A repeat sample from the avoidable repeat category must be taken within 3 calendar days of the receipt of the request
Standard 11
Timely receipt into clinical care A baby in whom an IMD (on first sample) is suspected should attend their first appointment by: Acceptable 100% by 17 days of age Achievable 100% by 14 days of age 5c
Clinical referral and management guidelines
Guidelines for Clinical Referral for each of the 6 IMD conditions are outlined below and are in line with the guidance endorsed by the IMD Screening Advisory Board.
Notes
From May 2018 the Bristol Newborn Screening Laboratory, in line with 2017/18
Commissioning Intentions, will be reviewing screening results on a Saturday morning. Any positive screens for the three conditions IVA, MCADD & MSUD will be repeated and confirmed and referred to the SW Regional Paediatric Metabolic team on a Saturday.
It will be the responsibility of the On-Call IMD Consultant to contact the family in the first instance. Contacting families at the weekend could be more problematic than during the week as the usual methods of communication may be unavailable. It is essential therefore that a local pathway to support the communication of positive screens arising on a Saturday morning is in place should there be any difficulties in contacting the family. This should include a local designated healthcare professional e.g. On-call midwife, who can be contacted by the IMD Consultant and who can provide local support. The local pathway should also describe an escalation process to be followed as outlined below. 1. Note parents should NOT be informed of a positive result if an appointment cannot be given for the same or next day e.g. parents should not be informed on a Friday unless an appointment is for that day or the Saturday. In this case contact should be deferred until after the weekend to the next working day 2. NSL informs the Specialist team who will inform the Designated team depending on baby's location.
(to take place within 24hrs of informing the parents For all 'Other disorder suspected' results the NSL will inform and discuss the result with the Specialist IMD team. The Specialist team will liaise with the relevant local paediatric team as required.
2.
Same day review is recommended for this category of screening result as the findings may be indicative of a condition requiring prompt investigation and management. Review of these cases as part of the national review of PKU Screening Programme indicated that the majority of these cases were inpatients at the time of the screening result (PKU Expert Group Report http://www.newbornscreening-bloodspot.org.uk).
3.
Further testing for disorders that may be associated with elevated phenylalanine and tyrosine levels should be undertaken. This will include at least full blood count, clotting, urea and electrolytes, bicarbonate, calcium, phosphate, split bilirubin, AST/ALT, alkaline phosphatase, gamma GT, albumin, cholesterol, triglycerides, urine organic acids (in particular succinyl acetone), galactose-1-phosphate uridyl transferase and plasma amino acids. If there is significant liver dysfunction advice should be sought from a liver unit.
MCADD Clinical Management guidelines*
ON THE SAME DAY 1. NSL informs the Specialist team who will inform the Designated team depending on baby's location. First review appointment arranged (to take place within 24hrs). NSL must provide the following: a. Hospital of birth b. Parent telephone number c. Telephone number of midwifery contact (Saturdays) 2. Specialist/designated team to CONTACT FAMILY (if family CANNOT BE CONTACTED see Note 1 page 17.) a. If infant well and feeding regularly: i.
Advise parents about regular feeding & emergency management if the infant becomes unwell including assessment at the local hospital as per b. below. Arrange face to face hospital review same or next working day ii.
Arrange for the family to receive the 'MCADD is suspected' leaflet and MCADD A&E letter and contact details of the Specialist team. iii.
Contact the paediatric team at the local or specialist hospital to inform them of the patient & make arrangements for assessment & management if the patient becomes unwell. b. If infant unwell/feeding poorly/doubts about clinical situation i.
Specialist team instruct parents to go to local hospital or specialist hospital A&E ii.
Specialist team to liaise with the hospital on call paediatric consultant (or Registrar) for assessment and initial management iii.
Fax 
Quality Management and Clinical Governance
Policy Rationale Local arrangements Professional responsible 1. The clinical governance group [insert local name] is responsible for arranging release of audit data to identified regional and national screening teams in line with Caldicott and Governance arrangements.
To monitor compliance and adherence to national standards and assist in future strategic planning and commissioning of screening services.
[insert local arrangements]. Local Clinical Steering Group.
2. Policies and procedures for the management and reporting of incidents arising from the screening programme should be in place and be consistent with NHS England guidance: Managing Safety Incidents in NHS Screening Programmes https://www.gov.uk/government/publications/managingsafety-incidents-in-nhs-screening-programmes
To ensure safe and coherent screening for the population in accordance with the national service specification.
3. Provision of appropriate information for inclusion in national or local registers/audits must be provided.
To assist in the monitoring of the outcomes of screening and incidence of IMD. 
